Brian Kaspar (via Twitter)
March 29, 2021 09:00 AM EDTUpdated April 2, 04:09 AM
People

Look­ing to leave Zol­gens­ma da­ta ma­nip­u­la­tion scan­dal be­hind, Bri­an Kas­par emerges at a new gene ther­a­py play­er

Nicole DeFeudis

Editor

A year af­ter get­ting blamed by No­var­tis for a da­ta ma­nip­u­la­tion scan­dal over its cost­ly gene ther­a­py Zol­gens­ma, Bri­an Kas­par has turned up on the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times